Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-07-18
2006-07-18
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
07078395
ABSTRACT:
There is provided use of a cyclic compound or a pharmaceutically active salt thereof in the manufacture of a medicament to prevent and/or inhibit and/or arrest cell cycling, wherein the cyclic compound comprises at least one ring,wherein Group I and Group II, independently of each other, are attached to a ring of the cyclic compound;wherein Group I is a hydrocarbyl or an oxyhydrocarbyl group; andwherein Group II is a group of the formulaX is P or S;when X is P, Y is ═O or S, Z is —OH and R is hydrocarbyl or H;when X is S, Y is ═O, Z is ═O, and R is hydrocarbyl or N(R1)(R2), wherein each of R1andR2is independently selected from H or a hydrocarbyl group.
REFERENCES:
patent: 5281587 (1994-01-01), Reed
patent: 5616574 (1997-04-01), Reed et al.
patent: 5763492 (1998-06-01), Johnson et al.
patent: 6476011 (2002-11-01), Reed et al.
patent: 0 934 949 (1999-08-01), None
patent: WO 93/05064 (1993-03-01), None
patent: 97/30041 (1977-08-01), None
patent: 93/05063 (1993-03-01), None
patent: 93/05064 (1993-03-01), None
patent: 97/32872 (1997-09-01), None
patent: 98/11124 (1998-03-01), None
patent: 98/24802 (1998-06-01), None
patent: WO 99/03876 (1999-01-01), None
patent: 99/27935 (1999-06-01), None
patent: 99/27936 (1999-06-01), None
patent: 99/64013 (1999-12-01), None
patent: 00/76487 (2000-12-01), None
Purohit et al. “Recent advances in the development of steroid sulphatase inhibitors.” J. Steroid Biochem. Molec. Biol. 69:227-238 (1999).
Purohit et al. “The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity.” J. Steroid Biochem. Molec. Biol. 64(5-6):269-275 (1998).
Purohit et al. “Inhibition of tumor necrosis factor &60 -stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol.” Biochemical and Biophysical Research Comm. 261:214-217 (1999).
Woo et al. “Active site directed inhibition of estrone sulfatase by nonsteroidal coumain sulfamates.”J. Med. Chem. 39:1349-1352 (1996).
Schwarz et al. “Synthesis of estrogen sulfamates: compounds with a novel endocrinological profile.” Steroids 61:710-717 (1996).
Cushman et al. “Synthesis antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicines binding site.” J. Med. Chem. 38:2041-2049 (1995).
Klauber et al. “Inhibition of angiogeneis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol.” Cancer Research 57:81-86 91997).
Woo et al., “Oestrone-3-O-(N-acetyl)sulphamate a potential molecular probe of the active site of oestrone sulphatase.” Bioorganic & Medical Chemistry Letters 7(24):3075-3080 (1997).
Lloyd Potter Barry Victor
Reed Michael John
Collison Angela M.
Cook Rebecca
Frommer Lawrence & Haug
Kowalksi Thomas J.
Sterix Limited
LandOfFree
Methods for treating or preventing cancer by preventing,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating or preventing cancer by preventing,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating or preventing cancer by preventing,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3599009